Jones Nicole S

Nicole S Jones sells 28,526 CI shares at $300.00 for $8,557,800; cuts holdings by 50.2% to 28,325 shares

Nicole S Jones executed a substantial open-market sale of 28,526 shares at $300.00 on 2025-08-15, reducing her Cigna Group holdings by exactly 50.2% from 56,851 to 28,325 shares. The transaction occurred at a price -17.6% below the 52-week high of $366.85, and the stock has risen 2.2% over the prior 30 days and fallen 4.7% over the prior 90 days. Jones's cross-ticker track record shows 4 prior sells with a 90-day well-timed rate of 33.33%, while her same-ticker history at CI spans 4 prior sales with only 1 of 3 measurable outcomes showing a negative 90-day return. The fundamental backdrop shows Cigna with strong revenue growth of 26.6% annually, a trailing P/E of 14.93, and a market cap of $80,641,640,738.25. Investors should note the magnitude of the position reduction and compare it against the company's stable valuation metrics and revenue expansion trajectory.

Nicole S Jones sold 4,904 shares of Cigna (CI) at $308.12; retains 29,421 shares post-transaction

Nicole S Jones executed a sale of 4,904 shares at $308.12, reducing her holdings by 14.3% to 29,421 shares. The current price of $308.86 is -15.8% from the 52-week high, and the stock has posted a 30-day change of +5.0% and a 90-day change of -6.4%. Across her cross-ticker track record, Jones' prior 3 open-market sells showed a 90-day well-timed rate of 50.00%, though her same-ticker history at CI presents mixed outcomes: 1 of her 2 prior measurable CI sells at the 90-day mark was well-timed. The sale occurs against a backdrop of Cigna's strong revenue growth of +26.6% year-over-year and solid fundamentals ($63.7B in latest quarterly revenue, $825.0M net income), though the P/E of 48.18 reflects a rich valuation relative to near-term earnings.

Jones Nicole S sold 22,030 shares of CI at $330.96 for $7,291,048.80 on 2024-08-12; stock now $334.90.

Jones Nicole S sold 22.0K shares (44.7% reduction in holdings) on 2024-08-12, reducing her position from 49.3K to 27.2K shares. The sale occurred at $330.96, and the stock has since moved to $334.90 (within the 52-week range of $257.49–$364.08). Examining her prior trades at Cigna, both previous sells on 2024-03-04 and 2023-08-21 showed positive 90-day returns (+3.6% and +2.1% respectively), indicating the insider has historically sold before rallies, not declines. Her cross-ticker track record similarly shows 0.00% well-timed rate with an average 90-day return of +2.8% after sells, meaning her sells have not preceded downturns. The current transaction follows this established pattern: a substantial reduction in holdings at a stock price within recent highs, without a clear macro or company-specific catalyst evident in the fundamentals ($60.5B revenue, $1.6B net income, +8.2% YoY growth, P/E 23.57).